Carving REMS Out of Oncology? FDA, ASCO Plan Follow-Up Workshop
This article was originally published in RPM Report
Executive Summary
FDA and the oncology community will continue discussions about the role of REMS in cancer care. The agency is clearly taking pushback from providers seriously.